Drug Trial Radar · NCT05182840
A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
714
Actual
Start
Jan 11, 2022
Primary completion
Jun 19, 2023
Study completion Jul 10, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jan 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin. In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine. In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine. Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call. Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Kidney Disease, Chronic
Interventions
BI 690517Drug
Film-coated tablets
Placebo to BI 690517Drug
Film-coated tablets
EmpagliflozinDrug
Empagliflozin
Placebo to empagliflozinDrug
Placebo to empagliflozin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All PatientsTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
- Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - All PatientsTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
- Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Placebo Matching EmpagliflozinTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
- Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - Patients With Background Therapy of Placebo Matching EmpagliflozinTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
- Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of EmpagliflozinTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
- Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) of MMRM Estimate - Patients With Background Therapy of EmpagliflozinTime frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Locations
203 sites in 29 countries. Site status is shown where the registry gives one.
Aventiv Research Inc.
Mesa, Arizona
AKDHC Medical Research Services, LLC
Phoenix, Arizona
Clearview Medical Research, LLC
Canyon Country, California
Pacific Renal Associates
Long Beach, California
Amicis Research Center
Northridge, California
Valley Clinical Trials, Inc.
Northridge, California
California Kidney Specialists
San Dimas, California
Colorado Kidney Care
Denver, Colorado
Clinical Research of Brandon LLC
Brandon, Florida
Horizon Research Group
Coral Gables, Florida
Elixia Fort Lauderdale, LLC
Fort Lauderdale, Florida
South Florida Research Institute
Lauderdale Lakes, Florida
San Marcus Research Clinic, Inc.
Miami, Florida
Total Research Group, LLC
Miami, Florida
Horizon Research Group, LLC
Miami, Florida
West Orange Endocrinology
Ocoee, Florida
Pines Care Research Center
Pembroke Pines, Florida
Elixia Tampa, LLC
Temple Terrace, Florida
Boise Kidney and Hypertension PLLC
Nampa, Idaho
Cedar Crosse Research Center
Chicago, Illinois
Kansas Nephrology Research Institute, LLC
Wichita, Kansas
Aa Mrc Llc
Flint, Michigan
Elite Research Center, LLC
Flint, Michigan
Clinical Research Consultants, LLC
Kansas City, Missouri
Forte Family Practice
Las Vegas, Nevada
New Mexico Clinical Research and Osteoporosis Center, Inc.
Albuquerque, New Mexico
Triad Internal Medicine
Asheboro, North Carolina
Lucas Research, Inc.
Morehead City, North Carolina
Diabetes & Endocrinology Associates of Stark County
Canton, Ohio
Cleveland Clinic
Cleveland, Ohio
Heritage Valley Medical Group
Beaver, Pennsylvania
Elixia Upland, LLC
Upland, Pennsylvania
Monument Health
Rapid City, South Dakota
Knoxville Kidney Center PLLC
Knoxville, Tennessee
Research Institute of Dallas
Dallas, Texas
Academy Of Diabetes, Thyroid And Endocrine, PA
El Paso, Texas
PrimeCare Medical Group
Houston, Texas
P&I Clinical Research, LLC
Lufkin, Texas
Simcare Medical Research, LLC
Sugar Land, Texas
Providence Medical Research Center
Spokane, Washington
Showing 40 of 203 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.